Short answer
BALCHEM CORP (BCPC) filed its Q3 2025 10-Q quarterly report on Oct 21, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $268M (up 11.5% year over year) with net income of $40M.
Q3 2025 key financials · XBRL
- Revenue
- $268M
- +11.5% YoY · +4.7% QoQ
- Net income
- $40M
- +19.1% YoY · +5.3% QoQ
- Operating margin
- 20.4%
- Gross margin
- 35.7%
- EPS (diluted)
- $1.24
- +20.4% YoY · +6.0% QoQ
Source: XBRL data from the BALCHEM CORP (BCPC) Q3 2025 10-Q on SEC EDGAR. USD.
BALCHEM CORP Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- New anti-dumping risk: EU provisional duties 95.4%-120.8% on Chinese choline chloride imports, effective July 1, 2025, final duties proposed 90.0%-115.9%
- Regulatory risk update: EU anti-dumping measures on choline chloride may restrict market access, investigation initiated October 2024 with final measures expected by end 2025
- Legal risk: Uncertain tax positions liabilities increased to $7,349K as of Sept 30, 2025, timing of settlement unknown
- Operational risk: Supply chain disruption risk remains due to geopolitical tensions and global health crises affecting manufacturing and sales outside the U.S.
- Financial risk: Cash increased to $65.1M; $58.2M held in foreign subsidiaries intended for reinvestment, potential withholding tax exposure upon repatriation
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other BALCHEM CORP quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.